Angion Biomedica Corp. (NASDAQ: ANGN) announces several strategic additions to its management team to support the future development and commercialization of ANG-3777
Angion Biomedica Corp. (NASDAQ: ANGN) presents late-breaking data on ANG-377 in delayed graft function at the American Society of Nephrology Kidney Week 2019.
Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) to merge with RDD Pharma creating new gastroenterology company focused on specialty, rare and orphan diseases.
Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) announced that three abstracts were accepted for presentations during the 2019 Digestive Disease Week (DDW) conference.
Neurotrope, Inc. (NASDAQ: NTRP) announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the research and clinical development of Bryostatin-1.
Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announced today the positive outcome of a pre-IND meeting held with the US Food and Drug Administration (FDA) to disscuss the Company’s development plan for Oral PTH for the treatment of osteoporosis.
Angion Biomedica Corp. (NASDAQ: ANGN), a late-stage clinical biopharmaceutical company focused on kidney diseases and other acute organ injuries, announces the recent closing of a $35 million equity private placement.
Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announced today that it has entered into a research collaboration and license agreement with Amgen in inflammatory disease and other serious illnesses.
Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) announced today that Patrick H. Griffin, M.D., F.A.C.P. has joined as the acting head of clinical development.
Angion Biomedica Corp. (NASDAQ: ANGN) and Sinovant Sciences today announced a collaboration and license agreement for BB3, which is shown to have improved renal function post-transplant.
Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announced today that it has received positive results from the first part of its pharmacokinetic (PK) and pharmacodynamic (PD) study in patients with hypoparathyroidism treated with its oral parathyroid hormone (PTH) drug.
Innovate Biopharmaceuticals, Inc. (“Innovate”) (NASDAQ: INNT) announces it intends to present at the Jefferies 2018 London Healthcare Conference. The conference is being held on November 14-15, 2018.
Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announced today the appointment of Faith L. Charles and Miranda J. Toledano to the company’s board of directors, effective immediately.
Innovate Biopharmaceuticals, Inc. (“Innovate”) (NASDAQ: INNT), announced it intends to present at the Ladenburg Thalmann 2018 Healthcare Conference. The conference is being held on October 2, 2018, at the Sofitel Hotel in New York City.
Neurotrope, Inc. (NASDAQ: NTRP), announces that Dr. Charles Ryan, Neurotrope's Chief Executive Officer, will present a company overview at the Ladenburg Thalmann 2018 Healthcare Conference in New York on Tuesday, October 2nd, 2018.
Entera Bio Ltd. (NASDAQ: ENTX and ENTXW)today announced the appointment of Arthur C. Santora II, MD, PhD as its new Chief Medical Officer, effective immediately.
Neurotrope Inc. (NASDAQ: NTRP)is announcing a collaboration with The Nemours / Alfred I. duPont Hospital for Children ("Nemours") to initiate a clinical trial in children with Fragile X Syndrome ("Fragile X").
